{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:43:44Z","timestamp":1773866624970,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bmc.2019.06.013","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T12:04:09Z","timestamp":1559822649000},"page":"3347-3357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562\/A02 cells"],"prefix":"10.1016","volume":"27","author":[{"given":"Mutta","family":"Kairuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaobo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Ghaleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.06.013_b0005","series-title":"Adv. Nutr.","first-page":"418","article-title":"World Cancer Report 2014","author":"Mcguire","year":"2016"},{"key":"10.1016\/j.bmc.2019.06.013_b0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000086183","article-title":"Mechanisms of drug resistance in cancer chemotherapy","volume":"14","author":"Luqmani","year":"2014","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.bmc.2019.06.013_b0015","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bmc.2019.06.013_b0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/molecules21070965","article-title":"Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer","volume":"21","author":"Du","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2019.06.013_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5","article-title":"BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy","volume":"60","author":"Reed","year":"2015","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmc.2019.06.013_b0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","article-title":"Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance","volume":"25","author":"Seguin","year":"2015","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bmc.2019.06.013_b0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/0008-5472.CAN-14-3225","article-title":"Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance","volume":"75","author":"Adorno-Cruz","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.06.013_b0040","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.2174\/1381612822666160302103646","article-title":"ABC transporters in the development of multidrug resistance in cancer therapy","volume":"22","author":"Dlugosz","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmc.2019.06.013_b0045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.bmc.2019.06.013_b0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.bi.58.070189.001033","article-title":"The Biochemistry of P-glycoprotein-mediated multidrug resistance","volume":"58","author":"And","year":"1989","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.bmc.2019.06.013_b0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/15680096113139990076","article-title":"P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives","volume":"13","author":"Binkhathlan","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.bmc.2019.06.013_b0060","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/med.20239","article-title":"Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression","volume":"32","author":"Nobili","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2019.06.013_b0065","first-page":"1967","article-title":"Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil","volume":"41","author":"Tsuruo","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.06.013_b0070","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Pinto","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2014.11.008","article-title":"P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review","volume":"6","author":"Abdallah","year":"2015","journal-title":"J Adv Res"},{"key":"10.1016\/j.bmc.2019.06.013_b0080","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.2174\/138161212802430530","article-title":"Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective","volume":"18","author":"Palmeira","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bmc.2019.06.013_b0085","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejmech.2017.06.047","article-title":"Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer","volume":"138","author":"Joshi","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0090","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejmech.2014.02.051","article-title":"SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity","volume":"76","author":"Nesi","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ijc.21827","article-title":"In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques","volume":"119","author":"Jekerle","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmc.2019.06.013_b0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Anticancer. Ther."},{"key":"10.1016\/j.bmc.2019.06.013_b0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2009.11.008","article-title":"Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel","volume":"627","author":"Kwak","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2019.06.013_b0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2017.01.010","article-title":"Medicinal attributes of 1,2,3-triazoles: current developments","volume":"71","author":"Dheer","year":"2017","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0115","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1039\/c3gc37004f","article-title":"\u201cAll-water\u201d one-pot diverse synthesis of 1, 2-disubstituted benzimidazoles: hydrogen bond driven \u2018synergistic electrophile\u2013nucleophile dual activation\u2019by water","volume":"15","author":"Kommi","year":"2013","journal-title":"Green Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0120","doi-asserted-by":"crossref","first-page":"9373","DOI":"10.1039\/C5OB01532D","article-title":"Synthesis of quinoxalines or quinolin-8-amines from N-propargyl aniline derivatives employing tin and indium chlorides","volume":"13","author":"Aichhorn","year":"2015","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cbdd.12301","article-title":"Discovery of novel P-glycoprotein-mediated multidrug resistance inhibitors bearing triazole core via click chemistry","volume":"84","author":"Liu","year":"2014","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2019.06.013_b0130","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1016\/j.bmc.2014.10.032","article-title":"Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents","volume":"22","author":"Jiao","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0135","first-page":"2952","article-title":"Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance","volume":"54","author":"Kang","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2019.06.013_b0140","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1016\/j.bmc.2018.03.045","article-title":"Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as P-glycoprotein-mediated multidrug resistance inhibitors","volume":"26","author":"Gao","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0145","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/cbdd.13338","article-title":"Design, design, synthesis and evaluation of a novel series of inhibitors reversing P-glycoprotein-mediated multidrug resistance","volume":"92","author":"Ghaleb","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmc.2019.06.013_b0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1989.306","article-title":"The MTT assay underestimates the growth inhibitory effects of interferons","volume":"60","author":"Jabbar","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2019.06.013_b0155","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0959-8049(01)00356-2","article-title":"The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7\/adr cells","volume":"38","author":"Fu","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2019.06.013_b0160","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.7314\/APJCP.2013.14.9.4983","article-title":"Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line","volume":"14","author":"Wang","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.bmc.2019.06.013_b0165","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1021\/jm900194w","article-title":"Modulation of multidrug resistance protein 1 (MRP1\/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives","volume":"52","author":"Wong","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.06.013_b0170","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0959-8049(94)90187-2","article-title":"A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes","volume":"30A","author":"Twentyman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2019.06.013_b0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bcp.2014.06.006","article-title":"Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1","volume":"90","author":"Wang","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2019.06.013_b0180","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1039\/C5OB00233H","article-title":"3-(Benzo[d][1,3]dioxol-5-ylamino)-N-(4-fluorophenyl)thiophene-2-carboxamide overcomes cancer chemoresistance via inhibition of angiogenesis and P-glycoprotein efflux pump activity","volume":"13","author":"Mudududdla","year":"2015","journal-title":"Org Biomol Chem"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619307758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619307758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:03:52Z","timestamp":1760835832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619307758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0968089619307758"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.06.013","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562\/A02 cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}